The device is the first non-invasive vagus nerve stimulator device to be cleared by the FDA for acute treatment of pain from migraines and episodic cluster headaches. The gammaCore Sapphire device is portable and easy-to-use and can be self-administered by patients as needed for pain. Unlike medications, the device offers no side effects with treatment.
GammaCore Sapphire is placed on a patient’s neck over the vagus nerve to stimulate the nerve fibers and reduce pain. The design features a sleeker, smaller handheld device with an easy grip, smoother stimulation surfaces for easy placement over the vagus nerve, intensity buttons on the side of the device for make therapy adjustments and a larger, brighter display to show status information.
The device has added functionality that allows it to be used for multiple years. It also has a rechargeable function with a reloadable refill capacity. GammaCore Sapphire can be activated monthly through a unique, prescription-only authorization code that is delivered through a radio-frequency identification (RFID) card that is sent through the mail to the patient.
“GammaCore Sapphire offers more convenience to patients with an enhanced design and added functionalities that make the therapy application more seamless and even more patient-centric than the device’s previous generation,” Dan Duhart, chief commercial officer of ElectroCore, said in a press release. “Constantly innovating to deliver the next-generation device is just one example of our commitment to providing relief to patients suffering from the debilitating pain of migraine and episodic cluster headaches.”
GamaCore Sapphire is prescribed by a physician and allows for treatment of multiple headaches up to 24 stimulations a day.